BACKGROUND: Pirfenidone (PFD) is a molecule that exhibits antifibrotic properties in a variety of in vitro and animal models of lung, liver and renal fibrosis. These pathologies share many fibrogenic pathways with an abnormal fibrous wound-healing process; consequently, tissue repair and tissue regeneration-regulating mechanisms are altered. OBJECTIVE: To investigate the usefulness of PFD as an antifibrotic agent in clinical and experimental models of fibrotic disease. CONCLUSIONS: There is a growing understanding of the molecular effects of PFD on the wound healing mechanism, leading to novel approaches for the management of fibrosis in lung, liver and renal tissues. Although the optimum treatment for fibrosis remains undefined, it is poss...
Intestinal fibrosis is a common complication of inflammatory bowel disease. So far, there is no safe...
Three important features must be considered when proposing therapeutic strategies in liver cirrhosis...
Chronic allograft dysfunction is a leading cause of allograft failure, morbidity, and mortality afte...
Pirfenidone is an orally active small molecule that has recently been evaluated in large clinical tr...
Background: Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease ...
Chronic allograft dysfunction is a leading cause of allograft failure, morbidity and mortality follo...
: Pirfenidone (PFD) slows the progression of idiopathic pulmonary fibrosis (IPF) by inhibiting the e...
Myocardial fibrosis is a common feature of several heart diseases. The progressive deposition of ext...
Abstract Background Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down ...
A fundamental process in the development and progression of heart failure is fibrotic remodeling, ch...
Background/Aims: Our group has been involved in searching for different strategies to ameliorate hep...
Myocardial fibrosis is an endogenous response to different cardiac insults that may become maladapti...
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with a poor p...
Intestinal fibrosis is a common complication of inflammatory bowel disease. So far, there is no safe...
Three important features must be considered when proposing therapeutic strategies in liver cirrhosis...
Chronic allograft dysfunction is a leading cause of allograft failure, morbidity, and mortality afte...
Pirfenidone is an orally active small molecule that has recently been evaluated in large clinical tr...
Background: Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease ...
Chronic allograft dysfunction is a leading cause of allograft failure, morbidity and mortality follo...
: Pirfenidone (PFD) slows the progression of idiopathic pulmonary fibrosis (IPF) by inhibiting the e...
Myocardial fibrosis is a common feature of several heart diseases. The progressive deposition of ext...
Abstract Background Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down ...
A fundamental process in the development and progression of heart failure is fibrotic remodeling, ch...
Background/Aims: Our group has been involved in searching for different strategies to ameliorate hep...
Myocardial fibrosis is an endogenous response to different cardiac insults that may become maladapti...
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with a poor p...
Intestinal fibrosis is a common complication of inflammatory bowel disease. So far, there is no safe...
Three important features must be considered when proposing therapeutic strategies in liver cirrhosis...
Chronic allograft dysfunction is a leading cause of allograft failure, morbidity, and mortality afte...